Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Drug Interactions: early-phase trial registry

3 of 7 indexed Drug Interactions trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Drug Interactions: 7 US clinical trials tracked, 3 recruiting.

Drug Interactions is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Repros Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition drug-interactions

OPEN 3 | RECR 43% | LATE 1 | EARLY 4 | RANK #2497 | SPON 1

Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)

ACL Tear71.4%ACL57.1%Drug Interactions (this)43%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Drug Interactions

Drug Interactions lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Drug Interactions on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Drug Interactions is recruiting below its size-band peers.

    3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Drug Interactions trials is spread across many organizations.

    Repros Therapeutics accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Typical Drug Interactions enrolment sits around 25 participants.

    Median target enrolment is 25 among the 7 trials that report a genuine target (sentinel values excluded). 4 of those (57.1%) plan for fewer than 100 participants.

  4. Drug Interactions research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 41

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 4 1

Named interventions

Most-linked intervention names on Drug Interactions records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Oxycodone Drug
2 trials
CYP2D6 probe Drug
1 trials
CYP2C19 probe Drug
1 trials
CYP2C9 probe Drug
1 trials
CYP1A2 probe Drug
1 trials
Proellex Drug
1 trials
Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa) Drug
1 trials
Octreotide acetate Drug
1 trials

US sites by state

Facility locations filed on Drug Interactions trials. A trial with sites in several states counts in each.

Colorado 2 trials
California 2 trials
Utah 1 trials
Tennessee 1 trials
New Jersey 1 trials
Kentucky 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Drug Interactions page

7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Drug Interactions condition card totals 7 registered trials; most-linked intervention Oxycodone; top US site state Colorado. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.